The Microbiota in Cancer: A Secondary Player or a Protagonist?

Area of Science:

• Microbiology
• Oncology
• Immunology

Background:

• The human body maintains a symbiotic relationship with its intestinal microbiota, crucial for numerous physiological functions.
• This microbiota acts as a metabolic organ, impacting digestion, metabolism, immune development, and defense.
• Emerging research highlights the microbiota's significant role in various pathologies, notably cancer.

Purpose of the Study:

• To explore the intricate relationship between the intestinal microbiota and cancer.
• To investigate the microbiota's influence on oncogenesis, tumor progression, and response to cancer therapies.
• To examine the interaction between the gut microbiota and the efficacy and side effects of antineoplastic drugs.

Main Methods:

• Review of current scientific literature on the gut microbiota and its role in cancer.
• Analysis of studies investigating the systemic effects of microbiota on tumor development.
• Examination of research on microbiota-drug interactions, particularly with antineoplastic agents.

Main Results:

• Gut dysbiosis is implicated in cancer initiation, progression, and treatment response.
• The microbiota exerts both local and systemic effects on tumor development.
• The gut microbiota significantly modulates the activity, side effects, and therapeutic efficacy of cancer drugs.

Conclusions:

• The intestinal microbiota is a key player in cancer development and treatment.
• Microbiota-targeted therapies show potential as an adjuvant strategy to enhance oncological treatments.
• Further research is warranted to explore the therapeutic manipulation of the microbiota for cancer management.